UBS Group
SXTP icon

UBS Group’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

UBS Group’s Portfolio SXTP Stock Details SXTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.9K Sell
13,592
-17,818
-57% -$28.7K ﹤0.01% 8055
2026
Q1 		$55K Buy
31,410
+31,041
+8,412% +$88.2K ﹤0.01% 7313
2025
Q4 		$750 Hold
369
– – ﹤0.01% 9826
2025
Q3 		$2.18K Buy
369
+365
+9,125% +$2.22K ﹤0.01% 9208
2025
Q2 		$33 Sell
4
-4,043
-100% -$40.5K ﹤0.01% 10085
2025
Q1 		$29.8K Buy
4,047
+3,027
+297% +$37.2K ﹤0.01% 7950
2024
Q4 		$26.3K Buy
1,020
+854
+514% +$18.8K ﹤0.01% 7706
2024
Q3 		$4.14K Buy
166
+22
+15% +$813 ﹤0.01% 8179
2024
Q2 		$8.72K Buy
+144
New +$9.14K ﹤0.01% 7784

Other funds holding SXTP

KCM
Kathmere Capital Management Wayne, Pennsylvania $1.89B AUM 26.04% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's SXTP Position: Q2 2026 in Review

UBS Group reduced its 60 Degrees Pharmaceuticals (SXTP) stake by 57% in Q2 2026, selling an estimated $28.7K and leaving 13,592 shares worth $23.9K. The position accounts for ﹤0.01% of the portfolio, ranked #8055.

UBS Group first reported a position in SXTP in Q2 2024 and has held it in 9 quarters since. The position peaked at $55K in Q1 2026. 4 funds tracked by Wall St. Rank hold SXTP as of Q2 2026.

  • UBS Group held 13,592 shares of 60 Degrees Pharmaceuticals worth $23.9K as of Q2 2026.
  • UBS Group sold 17,818 60 Degrees Pharmaceuticals shares in Q2 2026, an estimated $28.7K.
  • 60 Degrees Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8055 holding.
  • UBS Group first reported a position in 60 Degrees Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • UBS Group's 60 Degrees Pharmaceuticals position peaked at $55K in Q1 2026.
  • 4 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.